As of January 30, 2025, 40 countries across Europe had reported confirmed cases of monkeypox. So far, 8,481 cases have been confirmed in Spain, while 4,383 cases have been confirmed in France. In July 2022, the outbreak of monkeypox was declared to be a public health emergency by the World Health Organization. Distribution by age and gender The age group with the highest number of recorded monkeypox cases in Europe was those aged between 31 and 40 years old, amounting to nearly 10.8 thousand cases as of July 2024. This was followed by the age group of 18–30 years, which accounted for almost seven thousand cases. The majority of the cases were recorded among men, whereas the number of cases among women was less than five hundred. Monkeypox worldwide As of February 2025, there were approximately 132.8 cases of monkeypox reported worldwide, according to the World Health Organization. In Africa, the Democratic Republic of the Congo recorded 23.3 thousand suspected cases in the given year, of which only 5.5 thousand were actually confirmed. In Latin America, Brazil was the leading country with 11.2 confirmed cases, followed by Colombia and Mexico with over four thousand cases each, as of June 2024. Additional information regarding this outbreak of monkeypox can be found on our page on the subject.

Monkeypox Vaccine Market Outlook

According to our latest research, the global Monkeypox Vaccine market size reached USD 1.34 billion in 2024, reflecting a robust demand surge in response to recurring outbreaks and heightened global health vigilance. The market is poised for significant expansion, projected to hit USD 4.92 billion by 2033, growing at a compelling CAGR of 15.5% during the forecast period of 2025 to 2033. This impressive growth is primarily driven by increased investments in vaccine research, government-led immunization programs, and the urgent need for effective disease containment strategies in both endemic and non-endemic regions.

The primary growth factor fueling the Monkeypox Vaccine market is the rising incidence of monkeypox outbreaks worldwide, which has underscored the need for rapid and effective immunization solutions. With the World Health Organization and national health agencies issuing frequent alerts and advisories, there is a heightened sense of urgency to develop, stockpile, and distribute vaccines capable of curbing the spread of the virus. The ongoing threat of zoonotic transmission, particularly in regions with close human-animal interactions, has propelled governments and private sector stakeholders to accelerate funding for vaccine research and ensure robust supply chain mechanisms. Additionally, the cross-protection offered by certain smallpox vaccines against monkeypox has further intensified research and development activities, aiming to optimize efficacy and minimize side effects.

Another significant driver is the evolving regulatory landscape, which has become increasingly supportive of fast-tracked approvals and emergency use authorizations for monkeypox vaccines. Regulatory agencies, including the US FDA and the European Medicines Agency, have streamlined approval processes in response to public health emergencies, thereby facilitating quicker market entry for innovative vaccines. The presence of dedicated funding initiatives and global partnerships, such as those led by GAVI and CEPI, has further enhanced the capacity of vaccine manufacturers to scale production and meet surging demand. This supportive environment has not only attracted established pharmaceutical giants but also encouraged smaller biotech firms to enter the market with novel vaccine candidates.

Technological advancements in vaccine development and delivery platforms are also playing a pivotal role in market expansion. The adoption of next-generation vaccine technologies, such as recombinant and non-replicating vaccines, has improved both the safety profile and immunogenicity of monkeypox vaccines. These innovations have enabled manufacturers to cater to a broader spectrum of end users, including immunocompromised individuals, children, and the elderly. Furthermore, the integration of digital health solutions for vaccine tracking, distribution, and post-market surveillance has contributed to more efficient immunization campaigns, thereby bolstering overall market growth.

From a regional perspective, North America continues to dominate the Monkeypox Vaccine market, accounting for the largest share in 2024, followed closely by Europe and Asia Pacific. The high level of awareness, well-established healthcare infrastructure, and proactive government interventions have enabled rapid vaccination rollouts in these regions. Meanwhile, emerging economies in Asia Pacific and Latin America are witnessing accelerated growth, driven by increasing healthcare investments, rising disease awareness, and the expansion of immunization programs. The Middle East & Africa region, though currently representing a smaller market share, is expected to experience steady growth as governments intensify efforts to combat zoonotic diseases and improve vaccine accessibility.

Vaccine Type Analysis

The Monkeypox Vaccine market is segmented by vaccine type into Live Attenuated Vaccines, Non-Replicating Vaccines, Recombinant Vaccines, and Others, each contributing uniquely to the market’s overall

Tecovirimat Capsules Market Outlook

According to our latest research, the global Tecovirimat Capsules market size reached USD 1.27 billion in 2024, reflecting a robust demand driven by rising viral outbreak preparedness. With an impressive compound annual growth rate (CAGR) of 13.2% from 2025 to 2033, the market is forecasted to achieve a value of USD 3.74 billion by 2033. This accelerated growth is primarily attributed to increasing incidences of orthopoxvirus infections, expanding government stockpiling initiatives, and heightened public health awareness regarding antiviral therapies.

One of the most significant growth factors propelling the Tecovirimat Capsules market is the rising prevalence of orthopoxvirus infections such as smallpox, monkeypox, and cowpox globally. Recent outbreaks, particularly of monkeypox in both endemic and non-endemic regions, have underscored the urgent need for effective antiviral agents. Tecovirimat, being the first antiviral approved specifically for smallpox and recommended for other orthopoxvirus infections, has gained rapid traction among healthcare providers and public health agencies. The drug’s unique mechanism of action, which inhibits the viral envelope protein, prevents the spread of the virus within the host, making it an essential tool in outbreak management and emergency preparedness. This has led to increased procurement by governments and health organizations, further fueling market growth.

Additionally, the expanding role of Tecovirimat Capsules in national stockpiling programs and bioterrorism preparedness is a critical driver for market expansion. Governments across North America, Europe, and Asia Pacific have initiated strategic reserves of antiviral medications to mitigate the risks associated with potential biological threats. The COVID-19 pandemic has further highlighted the necessity for robust infectious disease preparedness, prompting policymakers to allocate greater resources towards antiviral stockpiles. This proactive approach has not only increased the demand for Tecovirimat Capsules but also stimulated investments in research and development for new dosage forms and combination therapies, thereby broadening the market landscape.

Furthermore, advancements in pharmaceutical distribution channels have significantly contributed to the accessibility and reach of Tecovirimat Capsules. The proliferation of hospital pharmacies, retail chains, and online pharmacies has streamlined the supply chain, ensuring timely availability of the medication even in remote and underserved regions. Telemedicine and e-prescription platforms have further facilitated patient access to antiviral therapies, particularly in the context of homecare and outpatient treatment settings. This enhanced distribution network, coupled with growing awareness campaigns about the importance of early intervention in viral infections, has played a pivotal role in sustaining market growth and addressing unmet medical needs worldwide.

From a regional perspective, North America continues to dominate the Tecovirimat Capsules market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States, in particular, has been at the forefront of antiviral stockpiling and emergency preparedness, supported by strong governmental funding and regulatory approvals. Europe has also witnessed significant growth due to coordinated public health initiatives and rising incidences of monkeypox. Meanwhile, the Asia Pacific region is expected to exhibit the highest CAGR over the forecast period, driven by increasing healthcare investments and growing awareness about orthopoxvirus threats. Latin America and the Middle East & Africa are gradually emerging as potential growth markets, supported by improving healthcare infrastructure and international collaborations for disease control.

Dosage Form Analysis

The Tecovirimat Capsules market is segmented by dosage form into 200 mg, 400 mg, and others, with each segment addressing speci

Monkeypox Treatment Market Outlook

According to our latest research, the global Monkeypox Treatment market size reached USD 2.3 billion in 2024, driven by a surge in disease outbreaks and heightened global health surveillance. The market is expected to expand at a robust CAGR of 7.8% from 2025 to 2033, reaching a projected value of USD 4.6 billion by 2033. This growth is primarily fueled by the increasing prevalence of monkeypox cases, expanding awareness of zoonotic diseases, and significant advancements in antiviral therapeutics and vaccine development. As per our latest research, the market's upward trajectory is supported by both governmental and private sector initiatives aimed at strengthening infectious disease preparedness and response.

The primary growth factor for the Monkeypox Treatment market is the rising incidence of monkeypox outbreaks in both endemic and non-endemic regions. Over the past few years, the world has witnessed multiple cross-border outbreaks, intensifying the need for effective therapeutic and prophylactic measures. The World Health Organization’s declaration of monkeypox as a public health emergency in 2022 heightened awareness and stimulated global demand for both established and novel treatment modalities. This urgency has catalyzed accelerated regulatory approvals for antiviral drugs, vaccines, and immunoglobulin therapies, thereby expanding the range of options available for healthcare providers and patients. Additionally, the persistent risk of zoonotic transmission due to increased human-wildlife interaction further sustains the demand for efficient monkeypox management strategies.

Technological advancements in drug discovery and vaccine development represent another critical growth driver for the Monkeypox Treatment market. The rapid progress in biotechnology, particularly in the areas of nucleic acid-based vaccines and next-generation antivirals, has enabled the development of more effective and safer treatment options. Pharmaceutical companies are leveraging advanced platforms such as mRNA technology, which has demonstrated efficacy in COVID-19 vaccines, to accelerate the pipeline for monkeypox therapeutics. These innovations, coupled with increasing investments in R&D from both public and private sectors, are expected to foster the introduction of new treatment modalities, thus broadening the market landscape and improving patient outcomes.

Governmental and international health organizations play a pivotal role in the growth of the Monkeypox Treatment market. Strategic collaborations between regulatory agencies, research institutes, and pharmaceutical companies have led to streamlined clinical trials and expedited drug approvals. Funding initiatives aimed at pandemic preparedness have resulted in large-scale stockpiling of vaccines and antiviral drugs, particularly in countries with vulnerable populations or a history of outbreaks. Furthermore, global health initiatives are focusing on strengthening healthcare infrastructure and improving access to monkeypox treatments in low- and middle-income countries. These collective efforts are anticipated to enhance the market’s reach and ensure equitable distribution of therapeutic solutions.

From a regional perspective, North America and Europe continue to dominate the Monkeypox Treatment market, accounting for a significant share of global revenues. The United States, in particular, has invested heavily in research, vaccine stockpiling, and public health campaigns to mitigate the spread of monkeypox. Europe’s proactive approach, characterized by robust surveillance systems and rapid deployment of resources during outbreaks, has also contributed to market expansion. Meanwhile, the Asia Pacific region is emerging as a high-growth market, driven by increasing disease awareness, expanding healthcare infrastructure, and rising investments in infectious disease management. Latin America and the Middle East & Africa are witnessing steady growth, albeit from a smaller base, due to enhanced disease surveillance and international aid programs.